Advanced Urothelial Carcinoma

Oncology
6
Pipeline Programs
6
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
2
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
267%
Small Molecule
133%
+ 3 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

FUJIFILM Pharma
FUJIFILM PharmaMA - Cambridge
1 program
1
PembrolizumabPhase 2Monoclonal Antibody
Karyopharm Therapeutics
1 program
1
PembrolizumabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT04856189TerminatedEst. Feb 2024
Bayer
BayerLEVERKUSEN, Germany
1 program
1
copanlisibPhase 1/2Small Molecule1 trial
Active Trials
NCT05687721Withdrawn0Est. Jun 2025
Flare Therapeutics
Flare TherapeuticsMA - Cambridge
1 program
1
FX-909Phase 1
M&
Merck & Co.RAHWAY, NJ
1 program
1
FX-909Phase 11 trial
Active Trials
NCT05929235Recruiting120Est. Jan 2028
LP
Lee's PharmaceuticalChina - Guangzhou
1 program
1
anti-PD-L1 antibodyPhase 11 trial
Active Trials
NCT04603846Unknown20Est. Aug 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Bayercopanlisib
Karyopharm TherapeuticsPembrolizumab
Merck & Co.FX-909
Lee's Pharmaceuticalanti-PD-L1 antibody

Clinical Trials (4)

Total enrollment: 140 patients across 4 trials

NCT05687721Bayercopanlisib

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

Start: Jun 2025Est. completion: Jun 20250
Phase 1/2Withdrawn
NCT04856189Karyopharm TherapeuticsPembrolizumab

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Start: Apr 2021Est. completion: Feb 2024
Phase 1/2Terminated
NCT05929235Merck & Co.FX-909

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

Start: Aug 2023Est. completion: Jan 2028120 patients
Phase 1Recruiting
NCT04603846Lee's Pharmaceuticalanti-PD-L1 antibody

A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma

Start: Sep 2020Est. completion: Aug 202320 patients
Phase 1Unknown

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
9m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
9m ago

Office Administrator

SystImmune
9m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
20m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
23m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
23m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 140 patients
6 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)